| Literature DB >> 27602222 |
Hajime Otsuka1, Keishi Sugino2, Yoshinobu Hata1, Takashi Makino1, Satoshi Koezuka1, Kazutoshi Isobe2, Naobumi Tochigi3, Kazutoshi Shibuya3, Sakae Homma2, Akira Iyoda1.
Abstract
The syndrome of combined pulmonary fibrosis and emphysema (CPFE) has been characterized by severely impaired gas exchange and poor survival. However, the clinical features of patients with lung cancer plus CPFE have remained elusive. The present study performed a retrospective analysis to examine the clinical characteristics and outcome of surgically resected patients with lung cancer plus CPFE. Among 831 patients with primary lung cancer who underwent surgical resection, 23 patients (2.8%) were diagnosed with CPFE and 9 patients (1.1%) with solely idiopathic pulmonary fibrosis (IPF). Thirty-five patients were stratified as the solely emphysema group with adjustment of the pathological stage. The clinicopathological characteristics of patients in the CPFE group and their outcomes were evaluated and compared with those with the solely IPF or solely emphysema groups. Within the CPFE group, no significant differences in survival between patients with post-operative acute exacerbation (AE; n=3) and those without AE (n=20) were noted; however, in the solely IPF group, patients with post-operative AE (n=4) had a significantly shorter survival than those without AE (n=5; P=0.022). The 5-year survival rate of patients in the CPFE, solely IPF and solely emphysema groups was 22, 22 and 58%, respectively. Furthermore, the CPFE and solely IPF groups showed a significantly shorter survival than the solely emphysema group (P=0.001 and 0.011, respectively). In conclusion, surgically resected lung cancer patients with CPFE had poor survival, which was, in contrast to that of lung cancer patients with solely IPF, not affected by AE.Entities:
Keywords: combined pulmonary fibrosis and emphysema; emphysema; interstitial lung disease; lung cancer; surgery
Year: 2016 PMID: 27602222 PMCID: PMC4998205 DOI: 10.3892/mco.2016.954
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450